Tempero Bio Secures $70M Series B to Advance TMP-301 and Revolutionize Addiction Treatments

Tempero Bio is excited to announce that we have successfully raised $70,000,000 in our latest funding round, marking a significant milestone in our mission to transform the treatment landscape for Substance Use Disorders and related conditions. As a clinical-stage biopharmaceutical company, we remain committed to pioneering innovative therapies that directly address the urgent needs of patients worldwide. This fresh capital injection will primarily accelerate the development of our lead therapeutic candidate, TMP-301, a potent, orally available mGluR5 negative allosteric modulator currently being evaluated for the treatment of Cocaine Use Disorder and Alcohol Use Disorder, with expanded potential to tackle Opioid and Polysubstance Use Disorders. With the strategic support of our portfolio partner, Aditum Bio—founded by distinguished leaders including former Novartis CEO Joe Jimenez and former President of NIBR Dr. Mark Fishman—we are uniquely positioned to advance our clinical programs and broaden our scope of discovery. The funding will not only drive the continued development of TMP-301 but also enable us to fortify our research capabilities, expand collaborative efforts, and streamline our path toward regulatory milestones. At Tempero Bio, our patient-centric approach, collaborative spirit, relentless curiosity, and courageous drive define our endeavors. We are grateful to our investors, partners, and the entire team who share our vision of creating impactful, science-driven solutions to combat Substance Use Disorders. As we embark on this exciting phase of growth and innovation, we affirm our commitment to delivering hope and healing to patients and communities affected by addiction.